Sign Up Today and Learn More About Neurophth Therapeutics Stock
Invest in or calculate the value of your shares in Neurophth Therapeutics or other pre-IPO companies through EquityZen's platform.
Neurophth Therapeutics Stock (NEUT)
Neurophth is China's first gene therapy company for ophthalmic diseases.
About Neurophth Therapeutics Stock
Founded
2016
Industries
Software, Artificial Intelligence, Data and Analytics
Neurophth Therapeutics Press Mentions
Stay in the know about the latest news on Neurophth Therapeutics
Neurophth Announces Completion of Patient Enrollment for Opvika® Phase I/II Clinical Trial in the U.S.
prnewswire • Apr 09, 2024
Neurophth Secures Australian Approval for Ophthalmic Gene ...
prnewswire • Dec 24, 2023
The biggest private biotech investments in August 2023
labiotech • Dec 24, 2023
Neurophth Announces First Patient Dosed in Phase I/II ...
prnewswire • Dec 24, 2023
Deals in brief: Meatable secures USD 35 million in funding ...
kr-asia • Dec 24, 2023
Neurophth Therapeutics Management
Leadership team at Neurophth Therapeutics
Chief Operating Officer & Chief Medical Officer
Zhang Xin
Chief Scientific Officer
Li Qiutang
Join now and verify your accreditation status to gain access to:
- Neurophth Therapeutics current valuation
- Neurophth Therapeutics stock price
- Available deals in Neurophth Therapeutics and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in Neurophth Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Neurophth Therapeutics through EquityZen funds. These investments are made available by existing Neurophth Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Neurophth Therapeutics stock?
Shareholders can sell their Neurophth Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
